Epidemiology of Parkinson Disease.

Parkinson disease (PD) is a common progressive neurodegenerative condition, causing both motor and non motor symptoms. Motor symptoms include stiffness, slowness, rest tremor and poor postural reflexes, whereas nonmotor symptoms include abnormalities of mood, cognition, sleep and autonomic function. Affected patients show cell loss in the substantia nigra pars compacta, and accumulation of aggregated alpha-synuclein into intracellular structures called Lewy bodies, within specific brain regions. The main known non modifiable risk factor is age. The neuroepidemiology of PD is complex with susceptibility genes and a number of modifiable risk factors that can increase and others that can mitigate risk and outcome.

[1]  B. Bloem,et al.  Effectiveness of multidisciplinary care for Parkinson's disease: A randomized, controlled trial , 2013, Movement disorders : official journal of the Movement Disorder Society.

[2]  P. Martínez-Martín,et al.  Relationship between sleep disorders and other non-motor symptoms in Parkinson's disease. , 2013, Parkinsonism & related disorders.

[3]  Bastiaan R Bloem,et al.  Gender differences in Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  A. Minagar,et al.  The spinal cord: a review of functional neuroanatomy. , 2013, Neurologic clinics.

[5]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[6]  Y. Ben-Shlomo,et al.  Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. , 2011, The Cochrane database of systematic reviews.

[7]  J. Jankovic,et al.  Parkinson disease subtypes. , 2014, JAMA neurology.

[8]  S. Bettiol,et al.  Alcohol Consumption and Parkinson’s Disease Risk: A Review of Recent Findings , 2015, Journal of Parkinson's disease.

[9]  J. Duarte,et al.  Natural History of Parkinson's Disease in the Province of Segovia: Disability in a 20 Years Longitudinal Study , 2015, Neurodegenerative Diseases.

[10]  C. Colosio,et al.  The role of pesticide exposure in the genesis of Parkinson's disease: epidemiological studies and experimental data. , 2013, Toxicology.

[11]  N. Bajaj,et al.  Does a specialist unit improve outcomes for hospitalized patients with Parkinson's disease? , 2014, Parkinsonism & related disorders.

[12]  A. Kishore,et al.  Do nonmotor symptoms in Parkinson's disease differ from normal aging? , 2011, Movement disorders : official journal of the Movement Disorder Society.

[13]  D. Aarsland,et al.  A systematic review of prevalence studies of depression in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[14]  A. Berardelli,et al.  Sleep disorders in Parkinson’s disease , 1998, Journal of Neurology.

[15]  R. Hauser,et al.  Nonmotor symptoms of Parkinson’s disease , 2006, Expert review of neurotherapeutics.

[16]  Pablo Martinez-Martin,et al.  Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients , 2007, Movement disorders : official journal of the Movement Disorder Society.

[17]  K. Winge Lower urinary tract dysfunction in patients with parkinsonism and other neurodegenerative disorders. , 2015, Handbook of clinical neurology.

[18]  D. Aarsland,et al.  Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease , 2012, Journal of Neurology.

[19]  P. Valkovič,et al.  Pain in Parkinson´s Disease: A Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life , 2015, PloS one.

[20]  Samuel M. Goldman,et al.  EPIDEMIOLOGY OF PARKINSON'S DISEASE , 1996, Neurologic Clinics.

[21]  G. Gillies,et al.  Sex differences in Parkinson’s disease , 2014, Frontiers in Neuroendocrinology.

[22]  R. Nussbaum,et al.  Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.

[23]  E. Pekkonen,et al.  Gut microbiota are related to Parkinson's disease and clinical phenotype , 2015, Movement disorders : official journal of the Movement Disorder Society.

[24]  Günther Deuschl,et al.  MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[25]  G. Halliday,et al.  The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years , 2008, Movement disorders : official journal of the Movement Disorder Society.

[26]  John D Sorkin,et al.  Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. , 2013, JAMA neurology.

[27]  P. Tuite Phase II safety, tolerability, and dose selection study of isradipine as a potential disease‐modifying intervention in early Parkinson's disease (STEADY‐PD) , 2013, Movement disorders : official journal of the Movement Disorder Society.

[28]  Edo Richard,et al.  Apathy in Parkinson's disease: A systematic review and meta‐analysis , 2015, Movement disorders : official journal of the Movement Disorder Society.

[29]  K. Safranow,et al.  Ophthalmological Features of Parkinson Disease , 2014, Medical science monitor : international medical journal of experimental and clinical research.

[30]  B. Bloem,et al.  Artistic occupations are associated with a reduced risk of Parkinson’s disease , 2015, Journal of Neurology.

[31]  J. Jankovic,et al.  Functional decline in Parkinson disease. , 2001, Archives of neurology.

[32]  J. Parkinson An Essay on the Shaking Palsy , 2002 .

[33]  C. Tanner,et al.  Traumatic brain injury in later life increases risk for Parkinson disease , 2015, Annals of neurology.

[34]  D. Aarsland,et al.  A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[35]  J. Hardy,et al.  Milestones in PD genetics , 2011, Movement disorders : official journal of the Movement Disorder Society.

[36]  A. Nicholas,et al.  Nonmotor symptoms in Parkinson's disease: expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem. , 2013, Neurologic clinics.

[37]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[38]  A. Seidler,et al.  Diet and Parkinson's disease I , 1996, Neurology.

[39]  B. Ritz,et al.  Head injury and risk for Parkinson disease , 2015, Neurology.

[40]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[41]  H. Braak,et al.  Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.

[42]  Xiang Gao,et al.  Prospective study of statin use and risk of Parkinson disease. , 2012, Archives of neurology.

[43]  C. Adler,et al.  MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI , 2011, Movement disorders : official journal of the Movement Disorder Society.

[44]  S. Cheon,et al.  Nonmotor symptoms more closely related to Parkinson's disease: Comparison with normal elderly , 2013, Journal of the Neurological Sciences.

[45]  D. Aarsland,et al.  Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. , 2003, Archives of neurology.

[46]  J. Perlmutter,et al.  Neurologist care in Parkinson disease , 2011, Neurology.

[47]  A. Lees,et al.  Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD , 2008, Neurology.

[48]  Richard L. Doty,et al.  Olfactory dysfunction in Parkinson disease , 2012, Nature Reviews Neurology.

[49]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[50]  J. Friedman,et al.  Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. , 2014, JAMA neurology.

[51]  R. Pfeiffer Non-motor symptoms in Parkinson's disease. , 2016, Parkinsonism & related disorders.

[52]  E. Horváth-Puhó,et al.  Vagotomy and subsequent risk of Parkinson's disease , 2015, Annals of neurology.

[53]  Bastiaan R Bloem,et al.  Nonpharmacological treatments for patients with Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[54]  L. Rushton,et al.  Pesticides and Parkinson’s Disease—Is There a Link? , 2005, Environmental Health Perspectives.

[55]  R. Sakakibara,et al.  A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders , 2016, Neurourology and urodynamics.

[56]  B. Ritz,et al.  Parkinson disease and smoking revisited , 2014, Neurology.

[57]  Bradley F. Boeve,et al.  REM Sleep Behavior Disorder and REM Sleep Without Atonia as an Early Manifestation of Degenerative Neurological Disease , 2012, Current Neurology and Neuroscience Reports.

[58]  Y. Ben-Shlomo,et al.  The motor phenotype of Parkinson's disease in relation to age at onset , 2011, Movement disorders : official journal of the Movement Disorder Society.

[59]  Z. Mari,et al.  The past, present, and future of telemedicine for Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[60]  D. Aarsland,et al.  Changes in motor subtype and risk for incident dementia in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[61]  M. Giugliano,et al.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration , 2015, Nature.

[62]  W. Poewe,et al.  Mortality in Parkinson's disease, a 20‐year follow‐up study , 2009, Movement disorders : official journal of the Movement Disorder Society.